9001-28-9

Factor IX is plasma zymogen key to blood coagulation systems. It has been used in studies of portal vein thrombosis (PVT) in hepatocellular carcinoma (HCC). It has been found that abnormalities in factor IX contribute to PVT in HCC patients. Additionally, it has been used in studies of changes in the coagulation system in patients with inflammatory bowel disease (IBD).

Haimaplex;Preconativ;Profilnine;Proplex;Prothromplex.

Factor IX, a naturally occurring plasma protein fraction, is a vital component of the normal blood clotting mechanism which is deficient in haemophiliacs who require replacement therapy for both the treatment and prevention of bleeding. Factor IX is extracted from the pooled plasma of a large number of donors and is presented as a concentrate. It has been recognized since 1984 that some viruses, and particularly the HIV (AIDS virus) could be transmitted to haemophiliacs from such preparations. As a result many regulatory authorities have issued new directives for the manufacture of blood products that avert this danger, by requiring the introduction of specific antiviral treatment measures during the manufacturing process. Manufacturers have withdrawn pre-existing preparations.

Factor IX is a 55 kDa single chain vitamin K-dependent plasma zymogen which plays a key role in the intrinsic and extrinsic blood coagulation systems.